CAMBRIDGE, Mass., Mar 30, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today filed its Annual Report
on Form 10-K for the year ended December 31, 2009 with the U.S.
Securities and Exchange Commission. The report is available on the
Investors section of Ironwood's website at www.ironwoodpharma.com.
In addition, any Ironwood stockholder can request a printed copy of the
annual report free of charge by contacting Investor Relations at
+1.617.621.8304 or ir@ironwoodpharma.com.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial
pharmaceutical company dedicated to the art and science of great
drugmaking. Linaclotide, Ironwood's first-in-class GC-C agonist, is
being evaluated in a confirmatory Phase 3 program for the treatment of
irritable bowel syndrome with constipation (IBS-C) and chronic
constipation. Ironwood also has a growing pipeline of additional drug
candidates in earlier stages of development. Ironwood is located in
Cambridge, Mass.
SOURCE: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Susan Brady, 617-621-8304
Corporate Communications
sbrady@ironwoodpharma.com
Copyright Business Wire 2010